Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Healthtrust
Johnson and Johnson
Cipla
Deloitte

Generated: August 23, 2019

DrugPatentWatch Database Preview

AXERT Drug Profile

  Try a free trial


See Plans and Pricing

« Back to Dashboard

When do Axert patents expire, and when can generic versions of Axert launch?

Axert is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in AXERT is almotriptan malate. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the almotriptan malate profile page.

Drug patent expirations by year for AXERT
Synonyms for AXERT
1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
1-[[3-(2-dimethylaminoethyl)-5-indolyl]methanesulphonyl]pyrrolidine
154323-57-6
1H-Indole-3-ethanamine, N,N-dimethyl-5-[(1-pyrrolidinylsulfonyl)methyl]-
1O4XL5SN61
23A576
A809522
AB01563047_01
AB01563047_02
AC-8799
AC1L3WYP
AJ-08395
AKOS015895080
Almogran
Almotrintan
Almotriptan
Almotriptan (USAN)
Almotriptan [USAN:INN:BAN]
Almotriptan;
AM84500
AN-689
ANW-44596
API0000366
BCP06539
BIDD:GT0048
BRD-K67601717-001-02-0
BSPBio_002731
C17H27N3O2S
CAS-154323-57-6
CCG-39569
CHEBI:520985
CHEMBL1505
CS-4530
CTK8B4281
D02824
DB-064033
DB00918
dimethyl(2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethyl)amine
DSSTox_CID_24289
DSSTox_GSID_44289
DSSTox_RID_80142
DTXSID5044289
EBD2201889
FC0030
FT-0651595
GTPL7110
HMS1922L13
HY-B0383A
I06-0492
KBio2_002408
KBio2_004976
KBio2_007544
KBio3_001951
KBioGR_001647
KBioSS_002414
L000846
LAS 31416
LAS-31416
LS-173461
N,N-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-3-yl)ethan-1-amine
N,N-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-3-yl)ethanamine
n,n-dimethyl-2-(5-(pyrrolidin-1-ylsulfonylmethyl)-1h-indol-3-yl)-ethanamine
N,N-dimethyl-2-[5-(1-pyrrolidinylsulfonylmethyl)-1H-indol-3-yl]ethanamine
N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine
N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine
N,N-dimethyl-5-[(1-pyrrolidinylsulfonyl)methyl]-1H-Indole-3-ethanamine
NCGC00095135-01
NCGC00095135-02
NCGC00095135-03
NCGC00095135-04
NCGC00095135-05
NSC-760092
NSC760092
Pharmakon1600-01505204
PNU-180638
Pyrrolidine, 1-(((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)-
Pyrrolidine, 1-[[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]-
SB19515
SCHEMBL1957
SPBio_000395
Spectrum_001884
SPECTRUM1505204
Spectrum2_000498
Spectrum3_001006
Spectrum4_001134
Spectrum5_001554
SR-05000001986
SR-05000001986-1
TC-133341
Tox21 111444
Tox21_111444
Tox21_111444_1
UNII-1O4XL5SN61
WKEMJKQOLOHJLZ-UHFFFAOYSA-N
ZINC18087

US Patents and Regulatory Information for AXERT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms AXERT almotriptan malate TABLET;ORAL 021001-001 May 7, 2001 AB RX Yes No   Try a Free Trial   Try a Free Trial   Try a Free Trial
Janssen Pharms AXERT almotriptan malate TABLET;ORAL 021001-002 May 7, 2001 AB RX Yes Yes   Try a Free Trial   Try a Free Trial   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for AXERT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms AXERT almotriptan malate TABLET;ORAL 021001-001 May 7, 2001   Try a Free Trial   Try a Free Trial
Janssen Pharms AXERT almotriptan malate TABLET;ORAL 021001-002 May 7, 2001   Try a Free Trial   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for AXERT
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 6.25 mg and 12.5 mg ➤ Subscribe   Try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Citi
Daiichi Sankyo
Merck
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.